Last reviewed 2026-05-31 · How we verify

[177Lu]Lu-ABY-271

Affibody · Phase 1 active Small molecule ✓ Verified May 2026

[177Lu]Lu-ABY-271 is a Small molecule drug developed by Affibody. It is currently in Phase 1 development.

[177Lu]Lu-ABY-271 is a binding agent that targets carbonic anhydrase 9. It works by binding to carbonic anhydrase IX, according to its mechanism as a carbonic anhydrase IX binding agent.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	[177Lu]Lu-ABY-271
Sponsor	Affibody
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[177Lu]Lu-ABY-271 CI brief — competitive landscape report
[177Lu]Lu-ABY-271 updates RSS · CI watch RSS
Affibody portfolio CI

Frequently asked questions about [177Lu]Lu-ABY-271

What is [177Lu]Lu-ABY-271?

[177Lu]Lu-ABY-271 is a Small molecule drug developed by Affibody.

Who makes [177Lu]Lu-ABY-271?

[177Lu]Lu-ABY-271 is developed by Affibody (see full Affibody pipeline at /company/affibody).

What development phase is [177Lu]Lu-ABY-271 in?

[177Lu]Lu-ABY-271 is in Phase 1.

Manufacturer: Affibody — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing